|18th May 2018
Precision medicine is set to revolutionise the healthcare sector, promising vastly improved outcomes for patients. However, as treatments become more precise, pharma companies will need to create more targeted commercial strategies. Meanwhile, the clinical trial recruitment process will become more challenging and a new series of stakeholders will emerge. These are just some of the barriers.
That’s why have dedicated the latest edition of our ‘Perspective’ magazine to this complex topic. We have combined the views of our in-house precision medicine experts and voices from key industry leaders to give you the latest information on the trend set to redefine healthcare as we know it – precision medicine.
In this edition of ‘Perspective’, we answer the following questions:
|27th August 2020
Precision and personalised medicines are more than products, they are services in their own right. So, how should pharma approach this uncharted territory to ensure targeted therapies work for patients?
|28th July 2020
At the beginning of the COVID-19 Pandemic, Senior Account Executive Lauren Fernandes took a course at the London School of Hygiene and Tropical Medicine to better understand how the global response to the virus and to ensure we were best positioned to serve our clients during this challenging time. She shares the key learnings and why understanding the epidemiology of the disease is integral for fighting it.
|14th July 2020
Blue Latitude Health, and our parent company Fishawack Health, have developed exclusive intellectual property, processes and tools to ensure you’re engaging customers in the right way. View our service one-pagers below to find out how we can help solve your challenges whether you’re in a medical, brand, portfolio or an above brand role.